Newborn Screening Programs and Follow-Up

Newborn screening is the largest genetic screening program in existence and the one families are least aware they participated in. It is run by states rather than nationally, which means the panel a baby receives depends on where they are born. This page covers the program and what happens after a positive screen; the assay methods themselves are covered in newborn screening.

• The RUSP (Recommended Uniform Screening Panel) is the federal advisory list of conditions recommended for universal newborn screening. It is a recommendation, not a mandate, so states decide their own panels and screened conditions vary by state. A family moving between states may have children screened for different conditions.
• Conditions are nominated and evaluated against evidence of benefit before being added to the RUSP, and the process is deliberately slow. Advocacy organizations are frequently the driving force behind nominations.
• The screen is a dried blood spot collected in the first days of life, usually at 24 to 48 hours, plus point-of-care pulse oximetry for critical congenital heart disease and a hearing screen. Timing matters: collection that is too early can miss conditions that require a period of feeding, and preterm or transfused infants have their own protocols and often need repeat screening.
• Short-term follow-up is the program's obligation, not the family's. State programs are responsible for locating the infant, ensuring confirmatory testing, and connecting to treatment. The infants who fall through are typically those whose families moved, lack a phone, or were discharged to an address that is no longer current.
• Time-critical conditions drive the design. For several conditions on the panel, the interval between a positive screen and treatment is measured in days and determines whether the child suffers irreversible harm. This is why programs accept a high false-positive rate.
• False positives are common and consequential. Positive predictive value for many screened conditions is low. Beyond the immediate anxiety, studies have documented persistent parental stress and altered perception of the child's health even after the child is confirmed unaffected, sometimes called the vulnerable child syndrome.
• Carrier identification is a byproduct. Screening for sickle cell disease and cystic fibrosis identifies carriers, which the family did not ask for and which has reproductive implications for the parents. How and whether this is communicated varies by program.
• Consent is generally opt-out, with mandatory screening in most states and religious or philosophical exemptions available. Many parents do not recall consenting or being informed.
• Residual dried blood spots are retained by states for varying periods and have been used for quality assurance and research, which has produced litigation and legislative change in several states over consent and retention.
• Long-term follow-up, meaning tracking outcomes across childhood, is the weakest part of most programs, so the long-run benefit of adding a condition is often poorly measured.

• An infant screens positive for a metabolic condition. The state program contacts the birth hospital and the family within 24 hours, confirmatory testing is arranged the same day, and treatment starts before symptoms. The program worked as designed, and the speed was the point.
• A family receives a call about a positive screen and hears it as a diagnosis. The counselor's first task is to reframe: a screen indicates the need for a confirmatory test, most positives are not affected, and the confirmatory result is what will answer the question.
• A newborn screen identifies sickle cell trait. The parents came for their child's result and leave with information about their own carrier status and reproductive risk that they had not sought. This requires counseling in its own right rather than a line on a results letter.
• A family who moved out of state two weeks after birth cannot be reached for a positive screen. The program escalates through the birth hospital, the primary care provider, and public health outreach. This is the most common failure point in the whole system.

• Do not assume a panel is uniform. State variation is real, and a child screened in one state may not have been tested for a condition assumed to be covered.
• Do not communicate a positive screen as a diagnosis. Most are not affected, and the framing sets up weeks of avoidable distress.
• Do not treat a carrier result as incidental noise. It carries reproductive implications for the parents and warrants counseling.
• Do not overlook preterm, transfused, or acutely ill infants, whose screens have separate protocols and often require repeat testing.
• Do not assume distress resolves when the confirmatory test is normal. Effects on parental perception of the child can outlast the medical resolution.